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INTRODUCTION
Among high-grade gliomas, childhood glioblastoma
multiforme (GBM) is particularly challenging in terms of
therapeutic treatment.1-5 Cerebral tumors are the most
frequent childhood solid neoplastic disorders and are the
primary cancer-related cause of death among children.1,3
Gliomas constitute approximately 60% of all cerebral
tumors, and approximately half of them are considered to
be high-grade malignant tumors.1 The prognosis for
recovery is conservative, and 5-year survival rates range
from 5% to 15%.2,6,7 This case report documents a GBM that
was located deep in the right cerebral hemisphere of a 9-
year-old child. Because this is a rare illness for a patient of
this age, we also provide a brief literature review to
supplement this case report.
CASE REPORT
A previously healthy 9-year-old girl with adequate
neuropsychomotor development was admitted to the
hospital with a 15-day-long hemiparesis and disorientation.
A skull computerized tomography (CT) scan showed a
deep-seated, irregularly shaped expansive lesion on the
right of brain, with peripheral contrast uptake that was
impinging on and obstructing the cerebrospinal fluid (CSF)
pathways (see Figure 1). We performed a ventriculoper-
itoneal shunting and stereoctatic biopsy of the lesion. The
histopathology showed a pleomorphic neoplasia, which was
associated with vascular neoformation, and necrosis with
elongated cells and hyperchromatic and pleomorphic nuclei
that had atypia and mitotic figures. The immunohistochem-
istry (see Table 1) was positive for the glial fibrillary acidic
protein (GFAP), Ki-67 proliferation antigen, and S-100
protein. These findings, along with the morphological
features and the presence of necrosis, confirmed the
diagnosis of GBM (see Figure 2). The patient, whose level
of consciousness improved with steroids but whose motor
functioning remained impaired, was referred to radio-
therapy. After 40 days, there was a significant neurological
worsening with hemiplegia and a fluctuating level of
consciousness. Skull CT and MRI results showed an
increase of the lesion size (see Figure 3). A craniotomy with
a partial tumor removal was performed to reduce the
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Figure 1 - Skull CT: Deep-seated cerebral lesion with an irregular outline, mass-effect, peripheral contrast uptake, and central necrosis.
Table 1 - Antigens that were used for the
immunohistochemistry.
Antigens Clone Result
Glial fibrillary acidic protein (GFAP) Policlonal Positive
Ki-67 cellular proliferation antigen M1B1 Positive
S-100 protein Policlonal Positive
Neu-N MAB377 Negative
CD45RB – leukocyte-common antigen
(pan-hematopoietic)
PD7/26/16&2B11 Negative
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intracranial hypertension. The patient died ten days after
the procedure.
DISCUSSION
Malignant gliomas are rare in childhood, comprising
approximately 6.5% of all intracranial neoplastic disorders
in the pediatric population. Although these gliomas may
occur in any anatomical site within the central nervous
system, they are most frequently located in the supratentor-
ial site.1,3,5 Males are slightly more affected than females
(male:female ratio = 1.5:1). In terms of histology, anaplastic
astrocytomas are characterized by hypercellularity, nuclear
atypia, mytotic figures, nuclear pleomorphism and vascular
proliferation; GBM also has associated necrosis.2,6
Children with high-grade gliomas present with a variety
of signs and symptoms that chiefly depend on their age and
the tumor localization. The rate of neurological impairment
is characteristically quick and may range from months to
days. Seizures may herald the onset, especially when
tumors are close to the cerebral cortex. Other common
clinical manifestations include hemiparesis, visual deficit,
headache, and, in some cases, signs of intracranial hyper-
tension due to an obstruction of the CSF pathways.2-8 In our
case, the first clinical manifestation was hemiparesis and
clouding of the consciousness, with rapidly evolving
intracranial hypertension despite partial removal of the
tumor.
A brain MRI is the investigational tool of choice for deter-
mining a GBM diagnosis.1-3,8 In this case, there was an
irregularly outlined, deep-seated cerebral lesion with a
mass effect, peripheral contrast uptake and central necro-
sis. Such findings are consistent with the literature.1,3
The treatment of malignant gliomas is still a challenge,
particularly in children. Chemotherapy and radiotherapy,
far from being satisfactory treatment options, are associated
with a significant rate of morbidity.9-12 Present day
treatment includes tumor resection, local radiotherapy,
Figure 2 - A, B: Histological sections of cerebral tissue showing areas of elongated cells with pleomorphic and hyperchromatic nuclei
that are associated with vascular neoformation and extensive hemorrhage and necrosis.
C: Immunohistochemistry positive for GFAP.
Figure 3 - CT (above) and MTI (below): A large lesion impinging on the thalamus and basal ganglia with peripheral contrast uptake and
central necrosis.
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and chemotherapy, which are approaches that promote an
improvement in the length of survival but do not seem to
change the inexorable course of the disease.1,3-5,13,14
Our patient developed obstructive hydrocephalus that
demanded ventriculoperitoneal shunting. A subsequent
stereotactic biopsy led to the histopathological confirmation
of GBM. We chose to perform radiotherapy and chemother-
apy. The quick, unfavorable evolution of the disease
precluded the use of chemotherapy and led us to try a
partial tumor resection for decompression, which was
ultimately unsuccessful.
The role of adjuvant chemotherapy for the treatment of
pediatric high grade gliomas (HGGs) was established in the
1980s,15 which is based on the results of a randomized
Children’s Cancer Group study using lomustine and
vincristine. Recently, studies have shown a small increase
in survival rates using temozolomide and lomustine to treat
pediatric HGGs.16 These studies have demonstrated that
surgery, chemotherapy, and radiotherapy were ineffective
in achieving long-term survival. There have only been
anecdotal reports of good results in the treatment of
glioblastoma in children. Further research on this disease
is needed so that better treatments may be developed to
improve the quality of life and prognosis of these patients.
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